Ipsen Acquires Epizyme to Expand Oncology Portfolio

BioMarin Pharmaceutical Completes Acquisition of Inozyme Pharma

May 16, 2025

Healthcare Services

BioMarin Pharmaceutical Inc. completed its all-cash acquisition of Inozyme Pharma, Inc. for $4.00 per share, valuing the deal at approximately $270 million. The transaction adds INZ-701, a late-stage enzyme replacement therapy being developed for ENPP1 Deficiency, to BioMarin’s enzyme therapies portfolio.

Ipsen to Acquire ImCheck Therapeutics

October 22, 2025

Biotechnology

Ipsen has entered into a definitive share purchase agreement to acquire ImCheck Therapeutics, a private French biotechnology company based in Marseille. Under the terms, ImCheck’s shareholders will receive EUR 350 million at closing, with downstream payments that could bring total consideration to up to EUR 1 billion, with closing expected by the end of Q1 2026 subject to approvals.

Ipsen Acquires Albireo Pharma

January 9, 2023

Biotechnology

Ipsen has agreed to acquire Albireo Pharma in a cash tender offer of $42.00 per share plus a contingent value right (CVR) tied to FDA approval in biliary atresia, in a transaction intended to expand Ipsen's Rare Disease portfolio. The acquisition brings Albireo's approved pediatric liver drug Bylvay (odevixibat) and a pipeline of bile-acid modulators into Ipsen's global R&D and commercial capabilities.

Amgen Completes Acquisition of Horizon Therapeutics plc

October 6, 2023

Biotechnology

Amgen completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, valuing the transaction equity at approximately $27.8 billion. The deal expands Amgen’s inflammation and rare-disease portfolio by adding Horizon’s first-in-class, early-in-lifecycle medicines such as TEPEZZA, KRYSTEXXA, and UPLIZNA.

AstraZeneca to Acquire EsoBiotec

March 18, 2025

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company developing in vivo cell therapies. The deal is valued at up to $1 billion on a cash and debt-free basis, with an initial $425 million payment upon closing plus up to $575 million in contingent milestone consideration. The transaction is expected to close in Q2 2025, subject to regulatory approvals.

AstraZeneca Acquires Icosavax

December 12, 2023

Biotechnology

AstraZeneca has entered into a definitive agreement to acquire Icosavax, a Seattle-based clinical-stage biopharmaceutical company, in a cash tender offer valuing the deal at approximately $0.8bn upfront and up to $1.1bn including contingent payments. The acquisition brings Icosavax's virus‑like particle (VLP) platform and Phase III‑ready combination RSV/hMPV vaccine candidate IVX‑A12 into AstraZeneca's Vaccines & Immune Therapies late‑stage pipeline to strengthen respiratory vaccine capabilities for older adults and vulnerable populations.